Abbmira Therapeutics

Executive Summary

Abbmira Therapeutics AG is a Swiss biotech company founded in 2021 and headquartered in Basel, dedicated to revolutionizing cancer treatment through first-in-class small molecule immunomodulatory drugs. The company's lead candidate, Compound42, targets tumor-associated macrophages (TAMs) to reprogram the tumor microenvironment and overcome immune evasion, aiming to drive durable anti-cancer immune responses. By focusing on TAMs, a key component of the tumor microenvironment, Abbmira addresses a critical mechanism of immune suppression that limits the efficacy of existing immunotherapies. The company is privately held with no disclosed funding or valuation, reflecting its early-stage status. Despite the promising science, the lack of clinical data and pipeline visibility introduces significant uncertainty. Abbmira's success hinges on advancing Compound42 through preclinical studies and into clinical trials, with potential to address unmet needs in solid tumors where checkpoint inhibitors have shown limited benefit.

Upcoming Catalysts (preview)

• Q2 2027IND-enabling studies completion60% success
• Q4 2027First-in-human Phase 1 trial initiation40% success
• Q3 2026Publication of preclinical proof-of-concept data70% success